Clinical Trial Update: An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment

View source ↗

Summary

An observational study evaluating adherence to anastrozole for early breast cancer; the study has completed and is sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ARIMIDEX (anastrozole)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Status: COMPLETED